TKTX Transkaryotic Therapies (MM)

TKT to Present at Two Upcoming Conferences CAMBRIDGE, Mass., July 23 /PRNewswire-FirstCall/ -- Transkaryotic Therapies, Inc. (NASDAQ:TKTX) today announced that Michael J. Astrue, President and Chief Executive Officer will present at two upcoming conferences: Banc of America's New Products, New Paradigms in Health Care Conference being held July 28-30, 2004 in Southampton, New York and Robert W. Baird's 2004 Small Cap Conference being held August 4-5, 2004 in New York, New York. Mr. Astrue will present at Banc of America's conference at 1:30 p.m. Eastern Time on Thursday, July 29, 2004. This presentation will focus on TKT's Hunter syndrome and Gaucher disease programs. In addition, he will participate in a panel discussion on generic biologics at Banc of America on Thursday, July 29, 2004 at 3:00 p.m. Eastern Time. Mr. Astrue will also present an overview of TKT's business activities at 1:20 p.m. Eastern Time on August 5, 2004 at the Robert W. Baird conference. A live audio webcast of these presentations will be available at http://www.tktx.com/ on TKT's Investor Information website under the Events category. A replay of the Banc of America presentation and panel discussion will be available until August 12, 2004 and a replay of the Robert W. Baird presentation will be available until August 19, 2004. About TKT Transkaryotic Therapies, Inc. is a biopharmaceutical company primarily focused on researching, developing and commercializing treatments for rare diseases caused by protein deficiencies. Within this focus, the company markets Replagal(TM), an enzyme replacement therapy for Fabry disease, and is developing treatments for Hunter syndrome and Gaucher disease. In addition to its focus on rare diseases, TKT intends to commercialize Dynepo(TM), its Gene- Activated(R) erythropoietin product for anemia related to kidney disease, in the European Union. TKT was founded in 1988 and is headquartered in Cambridge, Massachusetts, with additional operations in Europe, Canada and Latin America. Additional information about TKT is available on the company's website at http://www.tktx.com/. Gene-Activated(R) is a registered trademark and Replagal(TM) is a trademark of Transkaryotic Therapies, Inc. Dynepo(TM) is a trademark of Aventis Pharmaceuticals, Inc. Contact: Daniella M. Lutz Corporate Communications Manager (617) 349-0205 Logo: NewsCom: http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO AP Archive: http://photoarchive.ap.org PRN Photo Desk, 888-776-6555 or 212-782-2840 DATASOURCE: Transkaryotic Therapies, Inc. CONTACT: Daniella M. Lutz, Corporate Communications Manager, Transkaryotic Therapies, Inc., +1-617-349-0205 Web site: http://www.tktx.com/ Company News On-Call: http://www.prnewswire.com/comp/120657.html

Copyright